For decades, men with high-risk prostate cancer have routinely been told they need 18 to 36 months of androgen deprivation therapy (ADT) alongside radiation.
But what if 12 months is enough?
In this episode of the Dr. Geo Prostate Podcast, Dr. Geo Espinosa welcomes internationally recognized radiation oncologist Dr. Dan Spratt, Chair of Radiation Oncology at University Hospitals/Case Western Reserve University, to discuss groundbreaking research that could change how advanced prostate cancer is treated.
Together they explore the latest MARCAP consortium data suggesting many men may receive the same cancer control with significantly less hormone therapy—potentially reducing years of unnecessary side effects while maintaining excellent outcomes. They also discuss how physicians personalize treatment decisions, the growing role of artificial intelligence with Artera AI, and why the future of prostate cancer treatment may involve doing less, not more.
If you or someone you love is facing radiation therapy for prostate cancer, this episode provides one of the most important conversations happening in prostate cancer care today.
What You'll Learn
✔ Why 2-3 years of ADT may not be necessary for many patients
✔ The new evidence supporting approximately 12 months of hormone therapy
✔ Why longer hormone therapy can permanently affect testosterone recovery
✔ How physicians balance cancer control with quality of life
✔ The difference between NCCN guidelines and individualized patient care
✔ Which patients may still benefit from longer hormone therapy
✔ How AI (Artera AI) is helping personalize prostate cancer treatment
✔ Why prostate cancer care is shifting toward treatment de-intensification
✔ The future of precision medicine in radiation oncology
Episode Timestamps
00:00 Introduction
01:30 Meet Dr Dan Spratt
02:22 Why ADT Lasts Years
05:42 How ADT Helps Radiation
08:49 Personalizing ADT Duration
12:39 Guidelines and Real World Use
18:03 Who Needs Long Term ADT
21:13 Artera AI Explained
23:19 Old Data and Modern Outcomes
27:28 De Intensification Future
31:33 Biomarkers for Urologists
33:57 Choosing Artera vs Decipher
37:28 Final Takeaways and Outro
Key Discussion Points
- New MARCAP consortium analysis on ADT duration
- Radiation sensitivity and androgen deprivation
- Why many men never fully recover testosterone after prolonged ADT
- Balancing survival outcomes with quality of life
- Shared decision-making between physician and patient
- Genomic classifiers including Decipher
- AI biomarkers and Artera AI
- Personalized radiation oncology
- Modern imaging and PSMA PET
- De-intensifying prostate cancer treatment
- Precision medicine in localized prostate cancer
- The future of individualized prostate cancer care
Resources Mentioned
• MARCAP Consortium research on androgen deprivation therapy duration
• NCCN Prostate Cancer Guidelines (discussed throughout the episode)
• Artera AI clinical decision support platform (discussion)
• Decipher genomic classifier
• PSMA PET imaging
• MRI-guided prostate cancer staging
___________________________________
💪 Exclusive Membership
Want deeper insights? Join The Dr. Geo Prostate Podcast Exclusive Membership for curated transcripts, detailed show notes, expert resources, and member perks. → https://drgeo.com/membership
___________________________________
📌 Follow and Connect
📺 YouTube → Dr. Geo Prostate Podcast — https://www.youtube.com/@DrGeoProstatePodcast
🎧 All Episodes → Captivate.fm Archive — https://dr-geo-prostate-podcast.captivate.fm
📸 Instagram → https://bit.ly/DRGEO-INSTA-YT
📘 Facebook → https://bit.ly/POD-FB-DrGeo
💼 LinkedIn → https://bit.ly/DRGEO-LINKEDIN-YT
🛒 Supplements → XY Wellness https://bit.ly/3uJPC7Z | Mr. Happy https://bit.ly/3TE7tWE
🌐 DrGeo.com Website → https://bit.ly/43khht0
___________________________________
📣 Hashtags
#DrGeoProstatePodcast #ProstateHealth #ProstateCancer #MensHealth #IntegrativeUrology #Urology
___________________________________
⚠️ Disclaimer
This podcast is for educational purposes only and not medical advice. The views expressed are Dr. Geo’s and not those of his employer(s) or affiliated organizations. Use of this content is at your own risk. Geovanni Espinosa, N.D., assumes no liability for direct or indirect consequences, including economic loss, injury, illness, or death.
